Last updated on June 2019

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma


Brief description of study

This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain tumor and how well it works when given before and after surgery in treating patients with glioblastoma that has grown or come back and requires surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To evaluate the penetration of sapanisertib (MLN0128 [TAK-228]) across the blood brain barrier and achieve a concentration of 70 nM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma (GBM) patients. (Part I) II. To determine the ability of MLN0128 (TAK-228) to inhibit TOR complex (TORC)1/2 in the enhancing components of the tumor as determined by modulation of RPS6 phosphorylated Ser-235 (pS235) in reverse phase protein array (RPPA) assays. (Part II)

SECONDARY OBJECTIVES:

I. To evaluate the penetration of MLN0128 (TAK-228) across the blood brain barrier by determining its concentration in tissue resected from a non-contrast enhancing region of the tumor. (Part I) II. To assess the plasma pharmacokinetics of MLN0128 (TAK-228) in patients with recurrent GBM. (Part I) III. To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 in the non-enhancing components of the tumor as determined by modulation of RPS6 pS235 in RPPA assays. (Part II) IV. To assess the ability of MLN0128 (TAK-228) to inhibit TORC1/2 by evaluating pharmacodynamics (PD) markers by immunohistochemistry such as pS235, pS236, phosphorylated 4E-binding protein (p4EBP), phosphorylated-mechanistic target of rapamycin (serine/threonine kinase) (pmTOR), and AKTpSer473. (Phase II) V. To evaluate the safety profile of MLN0128 (TAK-228) in pre-operative patients with recurrent GBM.

VI. To estimate response rate, progression-free survival, and overall survival.

TERTIARY OBJECTIVES:

I. To perform mass spectrometry imaging (MSI) to qualitatively assess the ability of MLN0128 (TAK-228) to penetrate the blood brain barrier and enter tumor tissue in enhancing and non-enhancing regions of the tumor. (Part I) II. To determine ex-vivo sensitivity of tumor neurosphere cultures (patient derived cell lines [PDCL]) established from surgical specimens to MLN0128 (TAK-228). (Part II) III. To explore the potential association of tumor genotype with progression-free survival among patients treated with MLN0128 (TAK-228). (Part II) IV. To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 as determined by modulation of additional TORC1/2 markers in RPPA assays. (Part II)

OUTLINE

PART I:

COHORT A: Patients receive sapanisertib orally (PO) once daily (QD) for 7-9 days (including 2-4 hours before surgery). On day 0, patients undergo surgery. Within 45 days after surgery, patients receive sapanisertib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If patients do not demonstrate adequate sapanisertib tumor tissue concentrations, patients are enrolled in Cohort B.

COHORT B: Patients receive sapanisertib PO 2-4 hours before surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

PART II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 30 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo surgery on day 0. Within 30 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 2 months for 2 years, and then every 6 months thereafter.

Clinical Study Identifier: NCT02133183

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.